Explore

ImmunityBio Secures U.S. Agreement for Tokyo Strain of BCG to Address Bladder Cancer

ImmunityBio Secures U.S. Agreement for Tokyo Strain of BCG to Address Bladder Cancer

ImmunityBio Secures U.S. Agreement for Tokyo Strain of BCG to Address Bladder Cancer

FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements

FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements

FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements

ImmunityBio Secures U.S. Rights for Tokyo Strain of BCG to Address Shortage

ImmunityBio Secures U.S. Rights for Tokyo Strain of BCG to Address Shortage

ImmunityBio, Inc. has signed an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory for the Tokyo strain of BCG (Tokyo-172 BCG). This agreement aims to address the longstanding BCG shortage in the United States by providing a second potential source of BCG. The Tokyo strain has shown non-inferior efficacy compared to TICE BCG in a Phase III trial for high-grade non-muscle invasive bladder cancer. ImmunityBio plans to engage with the FDA to pursue approval for this strain, which has been used in Japan for nearly 30 years.

Regeneron and Parabilis Collaborate to Develop New Drug Class Targeting Undruggable Proteins

Regeneron and Parabilis Collaborate to Develop New Drug Class Targeting Undruggable Proteins

Regeneron and Parabilis Collaborate to Develop New Drug Class Targeting Undruggable Proteins

FDA Alignment and AI Integration Critical for Rare Disease Drug Development

FDA Alignment and AI Integration Critical for Rare Disease Drug Development

FDA Alignment and AI Integration Critical for Rare Disease Drug Development

ImmunityBio Secures U.S. Agreement for Tokyo Strain of BCG to Address Supply Shortage

ImmunityBio Secures U.S. Agreement for Tokyo Strain of BCG to Address Supply Shortage

ImmunityBio Secures U.S. Agreement for Tokyo Strain of BCG to Address Supply Shortage

FDA Approves AstraZeneca's Baxfendy, a New Class of Hypertension Drug

FDA Approves AstraZeneca's Baxfendy, a New Class of Hypertension Drug

FDA Approves AstraZeneca's Baxfendy, a New Class of Hypertension Drug

Beverly Davidson Presents Advances in Huntington’s Disease Gene Therapy at ASGCT 2026

Beverly Davidson Presents Advances in Huntington’s Disease Gene Therapy at ASGCT 2026

Geneticist Beverly Davidson, PhD, received the 2026 Outstanding Achievement Award from the American Society of Gene and Cell Therapy (ASGCT) for her work in developing gene therapies for central nervous system disorders, including Huntington’s disease (HD). Davidson's research focuses on improving adeno-associated viruses (AAVs) for CNS gene therapies, with a lead program targeting HD. Her work addresses challenges in gene therapy delivery to the brain, aiming to enhance scalability and potency for treating genetic diseases.

CREATE Secures $122 Million to Advance CAR T Therapy in Cancer and Autoimmune Diseases

CREATE Secures $122 Million to Advance CAR T Therapy in Cancer and Autoimmune Diseases

CREATE Secures $122 Million to Advance CAR T Therapy in Cancer and Autoimmune Diseases

Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase

Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase

Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase

CREATE Secures $122 Million to Advance CAR T Cancer and Autoimmune Therapies

CREATE Secures $122 Million to Advance CAR T Cancer and Autoimmune Therapies

CREATE Secures $122 Million to Advance CAR T Cancer and Autoimmune Therapies

FDA Clears Glooko's EndoTool IV Cloud for Hospital Insulin Dosing

FDA Clears Glooko's EndoTool IV Cloud for Hospital Insulin Dosing

FDA Clears Glooko's EndoTool IV Cloud for Hospital Insulin Dosing